|Articles|July 1, 1998

New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
Volume 4
Issue 7 Suppl

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Author(s)Alan H. Gradman, MD

Download PDF: Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Articles in this issue

over 27 years ago

Article

Participating Faculty

over 27 years ago

Article

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

over 27 years ago

Article

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

over 27 years ago

Article

Gene Polymorphism Influences Response to Angiotensin Blockade

over 27 years ago

Article

New Drug Class Offers Benefits in Heart Failure

over 27 years ago

Article

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

over 27 years ago

Article

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

over 27 years ago

Article

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

over 27 years ago

Article

What are the Pharmacological Differences Between Angiotensin II Antagonists

over 27 years ago

Article

Clinical Implications of Differences Between Angiotensin II Antagonists

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

A Health Economic Evaluation of Digital Digestive Care Management

ByMartha Shepherd, DO, MPH,Pen-Che Ho, MS,David Hines, BA,Jon Harris-Shapiro, BA,Dena Bravata, MD, MS,Christopher M. Whaley, PhD,K. Davina Frick, PhD,Emmanuel F. Drabo, PhD,Ron Z. Goetzel, PhD

January 21st 2026

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

ByShamsi Atefeh, PhD

January 15th 2026

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

ByMohamed M. Ali, MS,Scott Lunos, MS,Zachary Henderson, BSB,Michele Allen, MD, MS,Patricia Adam, MD, MSPH,Genevieve B. Melton, MD, PhD,Rubina Rizvi, MD, PhD

January 12th 2026

Subjective and Objective Impacts of Ambulatory AI Scribes

ByJulia Adler-Milstein, PhD,Orianna DeMasi, PhD,Hossein Soleimani, PhD,Sarah Beck, MDiv,Maria E. Byron, MD,Aris Oates, MD,Robert Thombley, BS,Jinoos Yazdany, MD, MPH,Sara G. Murray, MD, MAS

January 8th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Articles in this issue

Newsletter

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

A Health Economic Evaluation of Digital Digestive Care Management

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

Subjective and Objective Impacts of Ambulatory AI Scribes

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Novel CLL Therapies Prompt New Treatment Considerations

Congress Unveils Massive Funding Bill to Avert Shutdown

Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma

ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC

Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care